Key Drivers
- High margins
- Strong liquidity
- Rich multiples
AIAI Summary
IRadimed should be viewed as a high‑margin, cash‑rich niche replacement play whose upside is critically dependent on flawless commercial execution of the 3870 launch and a timely, low‑friction scale‑up at the new facility rather than multi‑year market disruption. Monitor sequential unit growth, working‑capital build vs. sell‑through, dividend coverage and early EU/Japan clearances closely, because any slips will materially compress the richly priced valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong liquidity
- •Rich multiples
Immuno‑Diagnostic Systems delivers high profitability, excellent liquidity and minimal leverage but carries significant valuation risk and a dividend pace that warrants monitoring.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Near support
- •Bearish momentum
IRMD is trading below its last‑month SMA (~$101.16), sitting near $98.70 support after a ~3.7% decline last month with RSI ~35–37—momentum favors sellers inside a $98.70–$105.11 range but a mean‑reversion bounce is possible.
Volatile swings with a sharp early‑March drop leading to recent weakness
Sentiment & News
Key News Insights:
- •AI/product tailwinds
- •Strategic deal potential
- •Investor outreach
IRadimed is drawing investor attention for potential near‑term upside driven by AI/product themes, strategic deal prospects and upcoming Roth Conference engagement.
Positive investor visibility and conference access should help catalyze re‑rating if management substantiates product and deal progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings